ITUS Corp. Moffitt enter into CRADA to develop CAR-T technology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ITUS Corp. said it has entered into a Cooperative Research and Development Agreement with Moffitt Cancer Center, to advance toward human clinical testing, a Chimeric Antigen Receptor T-Cell technology aimed initially at ovarian cancer, and eventually additional solid tumors.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

By the end of 2022, Toni Monteiro had no fight left in her. She had been battling a rare blood cancer for three years. Her husband had just died. She was at risk of being evicted from her Washington, DC, apartment. Also, her heart was failing. “You’re really under stress,” Monteiro recalls her physician saying. ...

VOICES of Black Women, the largest population study of Black women in the United States, will be the first of American Cancer Society’s large-scale population studies to be initiated using an AI-driven data management platform—promising to bring observational cancer research out of the age of Excel data files and email sharing.

Login